MAPK
As MAPKs são uma família de proteínas quinases envolvidas em uma variedade de processos celulares, incluindo crescimento, proliferação, diferenciação e respostas ao estresse. A via de sinalização MAPK consiste em várias camadas, incluindo ERK, JNK e p38 MAPKs, cada uma desempenhando papéis distintos na função celular. A desregulação da sinalização MAPK está ligada ao câncer, doenças inflamatórias e distúrbios metabólicos. Na CymitQuimica, oferecemos uma ampla gama de inibidores e ativadores de MAPK para apoiar sua pesquisa em biologia celular, transdução de sinais e mecanismos de doenças.
Foram encontrados 886 produtos de "MAPK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
AKP-001
CAS:<p>AKP-001 is a selective inhibitor of MAPK of the p38α isoform and is used in the study of immune and digestive disorders.</p>Fórmula:C21H13ClF2N4O2Pureza:99.50% - 99.92%Cor e Forma:SolidPeso molecular:426.8p38 MAPK Inhibitor
CAS:<p>p38 MAPK inhibitor is a potent inhibitor of p38 MAP kinase (IC50 = 35 nM). It inhibits senescence induced by the oncogene RAS.</p>Fórmula:C20H13ClFN3OPureza:99.91%Cor e Forma:SolidPeso molecular:365.79NMDAR/TRPM4-IN-2
CAS:<p>Potent NMDAR/TRPM4-IN-2 blocks NMDAR/TRPM4, protects brain and retinal neurons, and prevents mitochondrial dysfunction with an IC50 of 2.1 μM.</p>Fórmula:C11H19BrCl2N2Pureza:98.77%Cor e Forma:SolidPeso molecular:330.092SB 203580 sulfone
CAS:<p>SB 203580 sulfone, an analog of the p38 MAP kinase inhibitor SB 203580, inhibits IL-1 production in monocytes and binds competitively with CSAID binding proteins (CSBP), inhibiting stress response signaling. It exhibits an IC50 of 0.2 μM for IL-1 inhibition and 0.03 μM for CSBP-mediated signaling inhibition [1].</p>Fórmula:C21H16FN3O2SCor e Forma:SolidPeso molecular:393.43KRAS G12C inhibitor 49
CAS:<p>KRAS G12C inhibitor 49 is an orally active KRAS G12C inhibitor that exhibits antitumour effects.</p>Fórmula:C31H31ClN6O3Cor e Forma:SolidPeso molecular:571.07SOS1-IN-5
CAS:<p>SOS1-IN-5, a potent pyrimidine inhibitor, disrupts RAS-SOS1, blocking KRAS activation.</p>Fórmula:C26H31F3N4O5Cor e Forma:SolidPeso molecular:536.54KRAS inhibitor-12
CAS:<p>KRAS inhibitor-12 blocks KRAS G12C (IC50: 0.537 μM) and p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancer study.</p>Fórmula:C19H16Cl2FN5OSCor e Forma:SolidPeso molecular:452.33Ras inhibitor 134
CAS:<p>Ras inhibitor 134 can be used in studies about Ras.</p>Fórmula:C23H21ClFN5O3Cor e Forma:SoildPeso molecular:469.9SOS1-IN-8
CAS:<p>SOS1-IN-8 is an inhibitor of SOS1 and acts on SOS1-G12D (IC50: 11.6 nM) and SOS1-G12V (IC50: 40.7 nM).</p>Fórmula:C24H26F3N3O4Cor e Forma:SolidPeso molecular:477.48KRAS G12C mutant protein inhibitor A-1
CAS:<p>KRAS G12C mutant protein inhibitor A-1 can be used in studies about Ras.</p>Fórmula:C31H26ClF4N7O2Cor e Forma:SolidPeso molecular:640.03ERK1/2 inhibitor 7
CAS:<p>ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).</p>Fórmula:C23H22FN7OSCor e Forma:SolidPeso molecular:463.53GGTI-297
CAS:<p>GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).</p>Fórmula:C26H31N3O3SCor e Forma:SolidPeso molecular:465.61SOS1-IN-14
CAS:<p>SOS1-IN-14 是选择性的、有效的、口服具有活力的 SOS1 抑制剂 (IC50: 3.9 nM)。SOS1-IN-14 能够利用 P-糖蛋白介导的外排机制在肠道内被吸收。SOS1-IN-14 能够用于 KRAS 突变的癌症的研究，且抑瘤效果比 BI-3406 好。</p>Fórmula:C29H29F3N6O2Cor e Forma:SolidPeso molecular:550.57CMP3a
CAS:<p>CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.</p>Fórmula:C28H27F3N6O2SCor e Forma:SolidPeso molecular:568.61SOS1-IN-16
CAS:<p>SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 of</p>Fórmula:C30H31F3N4O3Pureza:98%Cor e Forma:SolidPeso molecular:552.59KRAS inhibitor-18
CAS:<p>KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.</p>Fórmula:C20H15ClF3N3O2SCor e Forma:SolidPeso molecular:453.87HPK1-IN-27
CAS:<p>HPK1-IN-27 inhibits HPK1 (MAP4K1), a kinase with potential for cancer treatment, per patent WO2019016071A1, compound 38.</p>Fórmula:C26H23F3N4O4Cor e Forma:SolidPeso molecular:512.48ZG1077
CAS:<p>ZG1077, a covalent KRAS G12C inhibitor, is utilized in non-small cell lung cancer (NSCLC) research.</p>Fórmula:C33H33F2N5O5SCor e Forma:SolidPeso molecular:649.71SOS1-IN-4
CAS:<p>SOS1-IN-4 is a potent inhibitor of SOS1 (IC50: 56 nM) and can be used in the study of KRAS-C12C/SOS1 interactions.</p>Fórmula:C24H29F2N4O2PCor e Forma:SolidPeso molecular:474.48KRAS G12C inhibitor 35
CAS:<p>KRAS G12C inhibitor 35 targets KRAS G12C in cancer research (CN112920183A, compound 3).</p>Fórmula:C31H27ClF2N6O3Cor e Forma:SolidPeso molecular:605.03AMG-548 hydrochloride (864249-60-5 free base)
<p>AMG-548 hydrochloride is an orally active and selective p38α inhibitor (Ki: 0.5 nM) and shows slightly selective over p38β (Ki: 36 nM) and >1000 fold selective</p>Fórmula:C29H28ClN5OPureza:98%Cor e Forma:SolidPeso molecular:498.02KRAS G12C inhibitor 21
CAS:<p>KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.</p>Fórmula:C34H30ClN3O4Cor e Forma:SolidPeso molecular:580.07KRAS G12C inhibitor 25
CAS:<p>KRAS G12C inhibitor 25 blocks SOS1-mediated GDP/GTP swap in KRAS-G12C mutants; IC50: 0.48 nM (WO2021216770A1, comp. 3).</p>Fórmula:C32H41N7O2Cor e Forma:SolidPeso molecular:555.71HPK1-IN-33
CAS:<p>HPK1-IN-33 inhibits HPK1 with 1.7 nM potency, reduces IL-2 in Jurkat cells with 286 nM EC50, and is less effective in HPK1 KO cells.</p>Fórmula:C18H16ClFN6Cor e Forma:SolidPeso molecular:370.81KRAS G12C inhibitor 53
CAS:<p>KRAS G12C inhibitor 53 (Compound 1) is a KRAS G12C inhibitor.</p>Fórmula:C21H14ClF2N5O2Cor e Forma:SolidPeso molecular:441.82HPK1-IN-11
CAS:<p>HPK1-IN-11 is a potent HPK1 inhibitor. HPK1-IN-11 has potential for the study of HPK1-related diseases.</p>Fórmula:C27H25N5O2Cor e Forma:SolidPeso molecular:451.52MS934
CAS:<p>MS934, a novel VHL-recruiting MEK 1/2 degrader, exhibits potent anti-proliferative effects on HT-29 cell growth, achieving a GI50 of 0.023 μM.</p>Fórmula:C52H69F3IN7O6SPureza:98%Cor e Forma:SolidPeso molecular:1104.11KRAS G12C inhibitor 32
CAS:<p>KRAS G12C Inhibitor 32, an eight-membered heterocyclic compound with nitrogen, acts as a potent inhibitor of KRAS G12C [1].</p>Fórmula:C29H30Cl3FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:635.94Org OD 02-0
CAS:<p>10-Ethenyl-19-norprogesterone (Org OD 02-0) is a selective agonist for the membrane progesterone receptor α (mPRα) with an IC50 of 33.9 nM, known to activate</p>Fórmula:C22H30O2Pureza:98%Cor e Forma:SolidPeso molecular:326.47B-Raf IN 15
CAS:<p>B-Raf IN 15 is a BRAF inhibitor that inhibits BRAFWT and BRAFV600E and can be used to study melanoma and cancer.</p>Fórmula:C19H15N3OSPureza:98%Cor e Forma:SolidPeso molecular:333.41DL-threo dihydrosphingosine
CAS:<p>DL-threo dihydrosphingosine blocks ERK, inhibits smooth muscle proliferation, and works against growth factor/G-protein ERK activation.</p>Fórmula:C18H39NO2Cor e Forma:SolidPeso molecular:301.51HPK1-IN-13
CAS:<p>HPK1-IN-13 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Cor e Forma:SolidPeso molecular:445.49Inflachromene
CAS:<p>Inflachromene (ICM) is an inhibitor of HMGB1 and HMGB expression with anti-inflammatory activity.Inflachromene is used in the study of epilepsy.</p>Fórmula:C21H19N3O4Pureza:97.36% - 99.88%Cor e Forma:SolidPeso molecular:377.39KRAS G12C inhibitor 61
CAS:<p>KRAS G12C inhibitor 61 (Example 3) demonstrates potent activity by inhibiting phospho-ERK 1/2 in MIA PaCa-2 cells, reflected in an IC50 value of 9 nM.</p>Fórmula:C31H33ClFN7O2Pureza:98%Cor e Forma:SolidPeso molecular:590.09Glecirasib
CAS:<p>Glecirasib (JAB-21822,KRAS G12C inhibitor 36) is an orally active KRAS G12C inhibitor that selectively binds to and inhibits KRAS G12C-dependent signaling</p>Fórmula:C31H26ClF4N7O2Pureza:99.7% - >99.99%Cor e Forma:SolidPeso molecular:640.03KRAS G12C inhibitor 30
CAS:<p>KRAS G12C inhibitor 30 is an inhibitor of KRAS G12C and can be used to study cancer.</p>Fórmula:C25H22ClFN6O3Cor e Forma:SolidPeso molecular:508.93L 731734
CAS:<p>L 731734 is a farnesyltransferase inhibitor.</p>Fórmula:C19H38N4O3SCor e Forma:SolidPeso molecular:402.6Pan-RAF kinase inhibitor 1
CAS:<p>Potent Pan-RAF inhibitor 1 targets RAF/MAPK pathway, curbing RAS-mutated cancer cell growth. (Patent WO2021110141A1, compound 16B)</p>Fórmula:C26H24F3N3O4Cor e Forma:SolidPeso molecular:499.48Laxiflorin B
CAS:<p>Laxiflorin B, a novel selective inhibitor of ERK 1/2 derived from herbal sources, exhibits antitumor activity [1].</p>Fórmula:C20H24O5Pureza:98%Cor e Forma:SolidPeso molecular:344.4KRAS G12C inhibitor 51
CAS:<p>KRAS G12C inhibitor 51 is a KRAS G12C inhibitor.</p>Fórmula:C33H35FN6O3Cor e Forma:SolidPeso molecular:582.67HPK1-IN-10
CAS:<p>HPK1-IN-10 inhibits HPK1, a MAP4K kinase from progenitor cells, with potential in treating HPK1 diseases, detailed in patent WO2021213317A1.</p>Fórmula:C31H34N6O2Cor e Forma:SolidPeso molecular:522.64SOS1/KRAS-IN-1
CAS:<p>SOS1/KRAS-IN-1 (Compound 2) serves as an inhibitor of SOS1/KRAS, with potential application in the study of diseases mediated by SOS1/KRAS [1].</p>Fórmula:C24H26F3N5OPureza:98%Cor e Forma:SolidPeso molecular:457.49GNE 220 hydrochloride
CAS:<p>GNE 220 (hydrochloride) is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H27ClN8Cor e Forma:SolidPeso molecular:474.99p38 Kinase inhibitor 4
CAS:<p>Compound 135, also known as p38 Kinase Inhibitor 4, is a potent inhibitor of p38 [1].</p>Fórmula:C12H9Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:282.13FGTI-2734 mesylate (1247018-19-4 free base)
CAS:<p>FGTI-2734 mesylate hinders KRAS, overcoming resistance and targeting pancreatic tumors; inhibits FT and GGT with IC50s of 250 nM, 520 nM.</p>Fórmula:C27H35FN6O5S2Pureza:98%Cor e Forma:SolidPeso molecular:606.73ERK-IN-2 free base
CAS:<p>ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.</p>Fórmula:C16H17N5O2Cor e Forma:SolidPeso molecular:311.34CXJ-2
CAS:<p>CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.</p>Fórmula:C55H87N15O22Pureza:98%Cor e Forma:SolidPeso molecular:1310.37Ilaprazole sodium hydrate
CAS:<p>Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.</p>Fórmula:C19H21N4NaO4SPureza:99.2%Cor e Forma:SolidPeso molecular:424.45B-Raf IN 16
CAS:<p>B-Raf IN 16, a BRAF inhibitor, belongs to cyclic iminopyrimidine derivatives and can be used for cancer or tumour research.</p>Fórmula:C20H19N5O3SPureza:99.31% - 99.78%Cor e Forma:SolidPeso molecular:409.46ERK1/2 inhibitor 5
CAS:<p>ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.</p>Fórmula:C28H32ClFN6O5Cor e Forma:SolidPeso molecular:587.04K-Ras G12C-IN-2
CAS:<p>K-Ras G12C-IN-2 is a covalent kras g12c inhibitor.</p>Fórmula:C21H27ClN4O3Pureza:98%Cor e Forma:SolidPeso molecular:418.92KRAS G12C inhibitor 40
CAS:<p>KRAS G12C inhibitor 40 targets KRAS G12C in cancer research (WO2021129824A1, compound 70).</p>Fórmula:C34H36ClFN10O2Cor e Forma:SolidPeso molecular:671.17ERK1/2 inhibitor 9
CAS:<p>ERK1/2 Inhibitor 9 (Probe 1), a covalent antagonist of ERK1/2, exhibits sub-micromolar efficacy in cellular assays (A375 GI50=0.47 μM) and facilitates the</p>Fórmula:C31H32ClN7O3Pureza:98%Cor e Forma:SolidPeso molecular:586.08FGTI-2734
CAS:<p>FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.</p>Fórmula:C26H31FN6O2SPureza:99.69%Cor e Forma:SolidPeso molecular:510.63GNE 220
CAS:<p>GNE-220 is a potent and selective inhibitor of MAP4K4 (IC50: 7 nM).</p>Fórmula:C25H26N8Pureza:98%Cor e Forma:SolidPeso molecular:438.53HPK1-IN-12
CAS:<p>HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.</p>Fórmula:C25H24FN5O2Cor e Forma:SolidPeso molecular:445.49XRP44X
CAS:<p>XRP44X (XRP 44X) is a potent inhibitor of Ras-Net (Elk-3) pathway.</p>Fórmula:C21H21ClN4OPureza:99.67%Cor e Forma:SolidPeso molecular:380.87MNK inhibitor 9
CAS:<p>MNK inhibitor 9 potently blocks MNK1/2 (IC50: 0.003 µM each), is cell-permeable, and useful for tumor research.</p>Fórmula:C25H29N9OCor e Forma:SolidPeso molecular:471.56KRAS inhibitor-11
<p>KRAS inhibitor-11 is a KRAS inhibitor .</p>Fórmula:C29H47N9O6Cor e Forma:SolidPeso molecular:617.74Raf inhibitor 3
CAS:<p>Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].</p>Fórmula:C18H19FN8O2SPureza:98%Cor e Forma:SolidPeso molecular:430.46GSK1790627
CAS:<p>GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].</p>Fórmula:C24H21FIN5O3Cor e Forma:SolidPeso molecular:573.36RAF mutant-IN-1
CAS:<p>RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).</p>Fórmula:C23H18Cl3FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:567.85ERK Inhibitor II (Negative control)
CAS:<p>ERK Inhibitor II, a control, blocks ERK and insulin receptor activation, aiding diabetes research.</p>Fórmula:C18H12N6OCor e Forma:SolidPeso molecular:328.33AZD4747
CAS:<p>AZD4747 is an inhibitor of the mutant GTPase KRASG12C that hasial antitumor activity for the study of pancreatic and colorectal adenocarcinoma.</p>Fórmula:C24H22ClFN2O3Pureza:99.36%Cor e Forma:SolidPeso molecular:440.89p38-α MAPK-IN-1
CAS:<p>p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with IC50 of 2300 nM and 5500 nM in EFC displacement assay and HTRF assay,respectively.</p>Fórmula:C27H35N5O3Pureza:99.93%Cor e Forma:SolidPeso molecular:477.6KRAS G12C inhibitor 14
CAS:KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor with an IC 50 of 18 nM [1].Fórmula:C24H19ClF2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:484.88KRAS G12C inhibitor 13
CAS:<p>KRAS G12C inhibitor 13 is a KRAS G12C inhibitor .</p>Fórmula:C40H46F3N7O4Pureza:98%Cor e Forma:SolidPeso molecular:745.83RPR203494
CAS:<p>RPR203494 is a pyrimidine analogue of the p38 inhibitor RPR200765A with an improved in vitro potency.</p>Fórmula:C26H29FN6O4Cor e Forma:SolidPeso molecular:508.54HPK1-IN-37
CAS:<p>HPK1-IN-37 (compound A85), with an IC50 value of 3.7 nM, is a potent inhibitor of HPK1.</p>Fórmula:C27H35N7O4Cor e Forma:SolidPeso molecular:521.61PROTAC KRAS G12C degrader-3
CAS:<p>PROTAC KRAS G12C Degrader-3 (Comp 283) serves as a potent degrader of KRAS G12C, utilized in cancer research [1].</p>Fórmula:C63H75ClN14O6Pureza:98%Cor e Forma:SolidPeso molecular:1159.81ERK1/2 inhibitor 8
CAS:<p>ERK1/2 inhibitor 8 is a potent inhibitor of ERK that acts on ERK2 (IC50: 0.48 nM).</p>Fórmula:C23H20ClN7O2SCor e Forma:SolidPeso molecular:493.97Deltasonamide 1
CAS:<p>Deltasonamide is a potent and selective inhibitor of PDE6δ‐KRas.</p>Fórmula:C30H39ClN6O4S2Cor e Forma:SolidPeso molecular:647.25(aS)-PH-797804
CAS:<p>(aS)-PH-797804 is a selective inhibitor of p38 MAPK, demonstrating inhibitory concentration (IC50) values of 26 nM for p38α and 102 nM for p38β. This compound exhibits anti-inflammatory activity [1] [2].</p>Fórmula:C22H19BrF2N2O3Cor e Forma:SolidPeso molecular:477.3JNK3 inhibitor-3
CAS:<p>JNK3 Inhibitor-3 selectively blocks JNK3 (>4.1 nM), crosses the blood-brain barrier, is orally active, and improves memory in dementia mice.</p>Fórmula:C26H25N7O2Pureza:98%Cor e Forma:SolidPeso molecular:467.52MEK-IN-6 hydrate
CAS:<p>MEK-IN-6 hydrate (compound 69), a MEK inhibitor, exhibits an IC50 value of 2 nM in A375 cells [1].</p>Fórmula:C18H22FN3O5SPureza:98%Cor e Forma:SolidPeso molecular:411.45MEK-IN-6
CAS:<p>MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making it</p>Fórmula:C18H20FN3O4SPureza:98%Cor e Forma:SolidPeso molecular:393.43KRas G12C inhibitor 1
CAS:<p>KRas G12C inhibitor 1 is a compound that inhibits KRas G12C.</p>Fórmula:C31H38N6O3Pureza:98%Cor e Forma:SolidPeso molecular:542.67TNIK&MAP4K4-IN-1
CAS:<p>TNIK&MAP4K4-IN-1 (compound A-39) is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, exhibiting IC50 values of 1.29 nM and <10 nM, respectively, in human</p>Fórmula:C25H23FN4O3Cor e Forma:SolidPeso molecular:446.47KRAS G12C inhibitor 34
CAS:<p>KRAS G12C inhibitor 34 is an inhibitor of KRAS G12C that can be used to study cancer research.</p>Fórmula:C32H32ClN5O3Cor e Forma:SolidPeso molecular:570.08KRAS G12C inhibitor 5
CAS:<p>KRAS G12C inhibitor 5 is a KRas G12C inhibitor.</p>Fórmula:C32H37N7O2Pureza:98%Cor e Forma:SolidPeso molecular:551.68pan-KRAS-IN-4
CAS:<p>Pan-KRAS-IN-4 (compound 5) is a potent KRAS inhibitor, demonstrating IC50 values of 0.37 nM for Kras G12C and 0.19 nM for Kras G12V [1].</p>Fórmula:C36H34F2N6O3Pureza:98%Cor e Forma:SolidPeso molecular:636.69SKF-86002 dihydrochloride
CAS:<p>p38 MAP kinase inhibitor</p>Fórmula:C16H14Cl2FN3SPureza:98%Cor e Forma:SolidPeso molecular:370.27K-Ras G12C-IN-1
CAS:K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C.Fórmula:C22H23Cl2N3O3Cor e Forma:SolidPeso molecular:448.34pan-KRAS-IN-3
CAS:<p>Pan-KRAS-IN-3 (Example 84) is a pan-KRAS inhibitor suitable for cancer research [1].</p>Fórmula:C33H32F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:587.63B-Raf IN 5
CAS:<p>B-Raf IN 5 is a potent inhibitor of the protein kinase B-Raf (IC50: 2.0 nM). B-Raf IN 5 resists rapid metabolism and does not bind to the secondary target PXR.</p>Fórmula:C23H18ClF3N6O3S2Cor e Forma:SolidPeso molecular:583.01AZ-TAK1
CAS:<p>"AZ-Tak1 inhibits TAK1 kinase (IC50=0.009mM), reduces p38/ERK levels, and induces apoptosis in Mino, SP53, Jeko cells with increasing efficacy at 0.1-0.5mM."</p>Fórmula:C25H28FN7O2Cor e Forma:SolidPeso molecular:477.53AMG-548 dihydrochloride (864249-60-5 free base)
<p>AMG-548 dihydrochloride: oral p38α inhibitor, Ki: 0.5 nM; less so for p38β, Ki: 36 nM; >> p38γ/δ; blocks LPS-induced TNFα, IC50: 3 nM.</p>Fórmula:C29H29Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:534.48HPK1-IN-35
CAS:<p>HPK1-IN-35 is a potent, selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM.</p>Fórmula:C30H32N8O3SCor e Forma:SolidPeso molecular:584.69Rac1-IN-3
CAS:<p>Rac1-IN-3 (Compound 2) is a Rac1 inhibitor exhibiting an inhibitory concentration 50 (IC50) of 46.1 μM [1].</p>Fórmula:C21H23N7O2Pureza:98%Cor e Forma:SolidPeso molecular:405.45BI-0474
CAS:<p>BI-0474: KRASG12C inhibitor, IC50=7.0 nM, blocks GDP-KRAS/SOS1, anti-tumor in NCI-H358 cells & lung cancer model, for cancer research.</p>Fórmula:C30H37N9O2SPureza:99.61%Cor e Forma:SolidPeso molecular:587.74(R)-VX-11e
CAS:<p>(R)-VX-11e is an isomer of VX-11e, a potent and selective ERK2 inhibitor with potential to inhibit tumor growth.</p>Fórmula:C24H20Cl2FN5O2Pureza:98.73%Cor e Forma:SolidPeso molecular:500.35KRAS G12C inhibitor 59
CAS:<p>KRAS G12C Inhibitor 59 is a compound with anticancer properties.</p>Fórmula:C32H39F6N7O5Pureza:98%Cor e Forma:SolidPeso molecular:715.69DT-061
CAS:<p>DT-061 is an orally bioavailable protein phosphatase 2A (PP2A) activator. It could be applied in the therapy of KRAS-mutant and MYC-driven tumorigenesis.</p>Fórmula:C25H23F3N2O5SPureza:98%Cor e Forma:SolidPeso molecular:520.52KRAS G12C inhibitor 16
CAS:<p>KRAS G12C inhibitor 16 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H21ClFN3O3Pureza:97.84%Cor e Forma:SolidPeso molecular:453.89KRAS G12C inhibitor 58
CAS:<p>KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].</p>Fórmula:C51H64ClF4N9O8SPureza:98%Cor e Forma:SolidPeso molecular:1074.62KRAS G12D modulator-1
CAS:<p>KRAS G12D modulator-1 (compound 6), a potent modulator of KRAS G12D, exhibits IC50 values ranging from 1-10 μM against NEA-G12D, PPI-G12D, and p ERK-AGS, and is</p>Fórmula:C30H36FN5O4Pureza:98%Cor e Forma:SolidPeso molecular:549.64pan-KRAS-IN-2
CAS:<p>Pan-KRAS-IN-2 (compound 6) is a broad-spectrum KRAS inhibitor exhibiting potent activity with IC50 values of ≤10 nM against KRAS wild type and its mutants (G12D</p>Fórmula:C34H34F2N4O3Pureza:98%Cor e Forma:SolidPeso molecular:584.66SB-682330A
CAS:<p>SB-682330A is a Raf kinase inhibitor.</p>Fórmula:C28H27N3O3Cor e Forma:SolidPeso molecular:453.53TC13172
CAS:<p>TC13172 is a potent, covalent MLKL inhibitor, selective over RIPK1/RIPK3. It blocks TSZ-induced necroptosis (EC50=2nM) and MLKL oligomerization at 100nM.</p>Fórmula:C17H16N4O5SPureza:98%Cor e Forma:SolidPeso molecular:388.4Cobimetinib racemate
CAS:<p>Cobimetinib racemate (Cobimetinib (racemate)) (GDC-0973 racemate) is a selective inhibitor of MEK.Cobimetinib racemate is also known as a mitogen-activated</p>Fórmula:C21H21F3IN3O2Pureza:98.00% - 99.71%Cor e Forma:SolidPeso molecular:531.31KRAS G12C inhibitor 17
CAS:<p>KRAS G12C inhibitor 17 is a potent KRAS G12C inhibitor.</p>Fórmula:C24H20ClF2N3O3Pureza:98%Cor e Forma:SolidPeso molecular:471.88ARS-1323-alkyne
CAS:ARS-1323-alkyne is a switch-II pocket (S-IIP) inhibitor and a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.Fórmula:C28H27ClF2N6O3Pureza:98.00% - 99%Cor e Forma:SolidPeso molecular:569ARS-1323
CAS:<p>ARS-1323 is the racemate of ARS-1620 and a mutant K-ras G12C inhibitor.</p>Fórmula:C21H17ClF2N4O2Pureza:99.53%Cor e Forma:SolidPeso molecular:430.84TH-Z827
CAS:<p>TH-Z827 is a mutant-selective inhibitor targeting KRAS(G12D) with an IC50 of 2.4 μM, demonstrating specificity by not binding to KRAS(WT) or KRAS(G12C).</p>Fórmula:C30H38N6OPureza:98%Cor e Forma:SolidPeso molecular:498.66HPK1-IN-9
CAS:<p>HPK1-IN-9: Potent MAP4K family kinase inhibitor targeting hematopoietic progenitor cells; potential in HPK1 diseases. (Patent WO2021213317A1)</p>Fórmula:C30H33N7O2Cor e Forma:SolidPeso molecular:523.63CHI-000-667
CAS:<p>CHI-000-667 can be used in studies about Ras.</p>Fórmula:C21H16ClNO4SCor e Forma:SolidPeso molecular:413.87KRAS G12C inhibitor 28
CAS:<p>KRAS G12C Inhibitor 28 is a compound that effectively inhibits the KRAS G12C mutation, exhibiting potent antitumor effects with an inhibitory concentration (</p>Fórmula:C33H36F2N5O4PCor e Forma:SolidPeso molecular:635.64SHP2-IN-22
CAS:<p>SHP2-IN-22, a potent SHP2 allosteric inhibitor, exhibits an IC50 value of 17.7 nM and effectively suppresses proliferation, migration, and invasion in MIA PaCa-</p>Fórmula:C23H22Cl2N8OCor e Forma:SolidPeso molecular:497.38ARQ-736
CAS:<p>ARQ 736 effectively targets and inhibits BRAF, crucial in MAPK pathway, beneficial for treating melanomas and certain colon cancers.</p>Fórmula:C25H25N8Na2O8PSCor e Forma:SolidPeso molecular:674.54Kras binder 12
CAS:<p>Kras binder 12 can be used in studies about Ras.</p>Fórmula:C29H47N9O6Cor e Forma:SoildPeso molecular:617.74KRAS degrader-1
CAS:<p>KRAS degrader-1 (compound 1) is a potent agent that selectively targets KRAS proteins for destruction via the autophagy-lysosomal degradation pathway [1].</p>Fórmula:C55H57Br2ClFIN8O7Cor e Forma:SolidPeso molecular:1283.25KRAS inhibitor FB9
CAS:<p>KRAS inhibitor FB9 can be used in studies about Ras.</p>Fórmula:C23H21ClF4N2O5Cor e Forma:SolidPeso molecular:516.87KRAS G12D mutation regulator 4
CAS:<p>KRAS G12D mutation regulator 4 can be used in studies about Ras.</p>Fórmula:C33H33FN6O2Cor e Forma:SolidPeso molecular:564.65JNK3 inhibitor-1
CAS:<p>JNK3 inhibitor-1: potent, selective, IC50 of 0.005 μM, orally bioavailable, brain-penetrant.</p>Fórmula:C21H17ClFN5O2SCor e Forma:SolidPeso molecular:457.91Uplarafenib
CAS:<p>Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.</p>Fórmula:C22H21F3N4O4SPureza:99.85%Cor e Forma:SolidPeso molecular:494.49KRAS G12C inhibitor 41
CAS:<p>KRAS G12C inhibitor 41 targets a key signaling protein, potentially aiding cancer research.</p>Fórmula:C36H37ClFN9O2Cor e Forma:SolidPeso molecular:682.19SOS1-IN-7
CAS:<p>SOS1-IN-7 (compound 18-p1) is a potent inhibitor of SOS1 and acts on SOS1-G12D (IC50: 20 nM) and SOS1-G12V (IC50: 67 nM).</p>Fórmula:C23H25F3N4O3Cor e Forma:SolidPeso molecular:462.46KRAS inhibitor-14
CAS:<p>KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.</p>Fórmula:C20H15Cl3FN3O2SCor e Forma:SolidPeso molecular:486.77KRAS G12C inhibitor 1R
CAS:<p>KRAS G12C inhibitor 1R can be used in studies about Ras.</p>Fórmula:C31H36ClFN6O2Cor e Forma:SoildPeso molecular:579.11SOS1-IN-13
CAS:<p>SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.</p>Fórmula:C21H22F3N3O2Cor e Forma:SolidPeso molecular:405.41HPK1 antagonist-1
CAS:<p>HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].</p>Fórmula:C28H29FN6O2Cor e Forma:SolidPeso molecular:500.57HG6-64-1
CAS:HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.Fórmula:C32H34F3N5O2Pureza:99.89%Cor e Forma:SolidPeso molecular:577.64Kras4B G12D-IN-1
CAS:<p>Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.</p>Fórmula:C16H21ClN2O4SPureza:99.75%Cor e Forma:SolidPeso molecular:372.87BI-2493
CAS:<p>BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.</p>Fórmula:C24H27N7OSPureza:97.74% - 99.88%Cor e Forma:SoildPeso molecular:461.58ZYF0033
CAS:<p>ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.</p>Fórmula:C26H30N4O2SPureza:99.70%Cor e Forma:SolidPeso molecular:462.61JWG-071
CAS:<p>JWG-071: First ERK5 kinase probe, BET inhibitor, 1 μM BRD4 IC, boosts ERK5 function and BRD4 selectivity.</p>Fórmula:C34H44N8O3Pureza:98.33%Cor e Forma:SolidPeso molecular:612.77Exarafenib
CAS:<p>Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.</p>Fórmula:C26H34F3N5O3Pureza:98.36% - 99.84%Cor e Forma:SolidPeso molecular:521.58Pan-RAS-IN-1
CAS:<p>Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.</p>Fórmula:C36H41Cl2F3N6O2Pureza:99.77%Cor e Forma:SolidPeso molecular:717.65MK-8353
CAS:<p>MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)</p>Fórmula:C37H41N9O3SPureza:96.15% - 97.19%Cor e Forma:SolidPeso molecular:691.84AZD4625
<p>AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.</p>Fórmula:C24H21ClF2N4O3Cor e Forma:SolidPeso molecular:486.9KU004
CAS:<p>KU004, a potent dual EGFR/HER2 inhibitor, exhibits anticancer properties. It inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of HER2, EGFR, and the downstream Akt and Erk pathways, primarily inducing apoptosis (Apoptosis) through the extrinsic pathway. Additionally, KU004 is a novel quinazoline derivative.</p>Fórmula:C29H27ClFN4O2PCor e Forma:SolidPeso molecular:548.98KRAS inhibitor-27
CAS:<p>KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.</p>Fórmula:C31H28ClF3N6O3SCor e Forma:SolidPeso molecular:657.106KRAS inhibitor-35
CAS:<p>KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.</p>Fórmula:C38H32F4N6O3SCor e Forma:SolidPeso molecular:728.76BBO-8520
CAS:<p>BBO-8520 is a dual KRASG12C inhibitor that blocks ON and OFF states, disables effector binding, suppresses signaling, and induces tumor regression.</p>Fórmula:C35H33F6N7O2SPureza:97.879%Cor e Forma:SolidPeso molecular:729.74KRAS ligand 5
CAS:<p>KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.</p>Fórmula:C30H30F2N4O4Cor e Forma:SolidPeso molecular:548.58p38α-MK2-IN-1
CAS:<p>p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.</p>Fórmula:C27H26F3N5O3Cor e Forma:SolidPeso molecular:525.522KRAS G12D inhibitor 19
CAS:<p>KRAS G12D inhibitor 19 (Compound 7) is used in cancer research [1]. As a specific inhibitor of KRAS G12D, it targets and potentially suppresses this mutation, which is frequently associated with various cancers.</p>Fórmula:C35H34F2N6O3Cor e Forma:SolidPeso molecular:624.68KRAS inhibitor-8
CAS:<p>KRAS inhibitor-8 is a potent KRAS G12C inhibitor.</p>Fórmula:C26H24ClF4N5O3Pureza:98%Cor e Forma:SolidPeso molecular:565.95RGT-018
CAS:<p>RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.</p>Fórmula:C27H24F3N7O2Cor e Forma:SolidPeso molecular:535.52PF-03715455
CAS:<p>PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.</p>Fórmula:C35H34ClN7O3S2Pureza:98%Cor e Forma:SolidPeso molecular:700.27J-104871
CAS:<p>J-104871 (UNII-6137X5QNJF) is an FTase inhibitor that inhibits tumor growth in nude mice transplanted with activated H-ras-transformed NIH3T3 cells.</p>Fórmula:C38H32N2O12Pureza:98%Cor e Forma:SolidPeso molecular:708.67PS-166276
CAS:<p>PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.</p>Fórmula:C20H30N8OCor e Forma:SolidPeso molecular:398.51Luvometinib
CAS:<p>Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.</p>Fórmula:C26H22F2IN5O4SCor e Forma:SolidPeso molecular:665.45KRAS inhibitor-31
CAS:<p>KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.</p>Fórmula:C33H30F3N5O4Cor e Forma:SolidPeso molecular:617.62KRAS G12D inhibitor 16
CAS:<p>KRAS G12D inhibitor 16 targets KRAS G12D with IC50 of 0.7 nM and mutant form at 0.35 μM, useful in various cancer studies.</p>Fórmula:C32H39IN6O3Cor e Forma:SolidPeso molecular:682.59KRAS inhibitor-32
CAS:<p>KRAS inhibitor-32 (compound 139A) is a KRAS inhibitor utilized in cancer research.</p>Fórmula:C29H35FN10OS2Cor e Forma:SolidPeso molecular:622.78KRas G12C inhibitor 2
CAS:<p>KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.</p>Fórmula:C32H37N7O3Pureza:98%Cor e Forma:SolidPeso molecular:567.68KRAS inhibitor-37
CAS:<p>KRAS inhibitor-37 (compound 2) is a potent inhibitor of KRAS, exhibiting low dissociation constants (KD) with various KRAS mutations: wild type (0.004 nM), G12D (0.041 nM), G12C (0.019 nM), and G12V (0.144 nM). This compound effectively inhibits cell proliferation, demonstrating half-maximal inhibitory concentrations (IC50) ranging from <2 nM to 14 nM in H358, SW620, and PANC08.13 cell lines. KRAS inhibitor-37 holds potential for cancer research applications.</p>Fórmula:C32H33ClFN7O3Cor e Forma:SolidPeso molecular:618.10JNK-1-IN-4
CAS:<p>JNK-1-IN-4 (Compound E1) is an inhibitor of JNK, targeting JNK-1, JNK-2, and JNK-3 with IC50 values of 2.7, 19.0, and 9.0 nM, respectively. This compound inhibits the phosphorylation of c-Jun and reduces the expression of TGF-β1-induced EMT markers (such as fibronectin and α-SMA). JNK-1-IN-4 exhibits favorable pharmacokinetic properties with a bioavailability of 69%. Additionally, it demonstrates antifibrotic effects in a Bleomycin-induced mouse model of idiopathic pulmonary fibrosis.</p>Fórmula:C22H25BrN6O3Cor e Forma:SolidPeso molecular:501.38KRAS G12C inhibitor 20
CAS:<p>KRAS G12C inhibitor 20 is a KRAS G12C inhibitor.</p>Fórmula:C33H37ClFN7O3Cor e Forma:SolidPeso molecular:634.14FMK-MEA
CAS:<p>FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.</p>Fórmula:C21H26FN5O2Pureza:98%Cor e Forma:SolidPeso molecular:399.46KRAS G12D inhibitor 26
CAS:<p>KRAS G12D inhibitor 26 (Compound 64B) is an inhibitor of KRAS G12D with an IC50 ≤ 100 nM.</p>Fórmula:C35H44ClFN8O2Pureza:99.93%Cor e Forma:SolidPeso molecular:663.23SR-302
CAS:<p>SR-302 is a potent and selective inhibitor of DDR/p38, with IC50 values of 0.125 μM for p38α, 0.023 μM for DDR1, and 0.018 μM for DDR2. It is utilized in research related to fibrotic diseases, such as kidney and lung fibrosis, atherosclerosis, and various types of cancer.</p>Fórmula:C32H42N6O5SCor e Forma:SolidPeso molecular:622.778(R)-STU104-d6
CAS:<p>(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.</p>Fórmula:C18H182D6O4Cor e Forma:SolidPeso molecular:304.37pan-KRAS degrader 1
CAS:<p>Pan-KRAS degrader 1 (Compound 1) is a broad-spectrum KRAS degrader, exhibiting an inhibitory constant Ki value of 25 nM against KRASG12V as determined by surface plasmon resonance (SPR). Additionally, this compound demonstrates antitumor activity.</p>Fórmula:C22H26N8OSCor e Forma:SolidPeso molecular:450.56KRAS G12C inhibitor 56
CAS:<p>KRAS G12C inhibitor 56, a powerful inhibitor of SOS1 with an inhibitory concentration (IC50) of 1.6 nM, holds promise for use in cancer research.</p>Fórmula:C32H39N7O4SCor e Forma:SolidPeso molecular:617.76p38α MAPK/CK1δ inhibitor-1
CAS:<p>p38αMAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38αMAPK and CK1δ, with IC50 values of 0.185 µM and 0.089 µM, respectively.</p>Fórmula:C24H17FN6O2Cor e Forma:SolidPeso molecular:440.429MRTX849 acid
CAS:<p>MRTX849 acid, used to make PROTAC LC-2, effectively degrades KRAS G12C at 0.25-0.76 μM DC50.</p>Fórmula:C34H37ClFN7O4Cor e Forma:SolidPeso molecular:662.16MRTX-EX185
<p>MRTX-EX185 inhibits GDP-KRAS/G12D; IC50=90 nM on G12D. It also binds GDP-HRAS.</p>Fórmula:C33H33FN6O2Cor e Forma:SolidPeso molecular:564.65KRASG12C IN-15
CAS:<p>KRASG12C IN-15 (Compound 21) is an orally active KRASG12C inhibitor that effectively blocks SOS1-mediated GDP/GTP exchange with an IC50 of 19 nM. It inhibits ERK phosphorylation with an IC50 of 0.051 μM and reduces the viability of KRASG12C mutant MIA PaCa-2 cells with an IC50 of 0.023 μM. Additionally, KRASG12C IN-15 demonstrates antitumor activity in a MIA PaCa-2 xenograft mouse model.</p>Fórmula:C31H32FN3O2Cor e Forma:SolidPeso molecular:497.603KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Fórmula:C22H17ClF2N6OSCor e Forma:SolidPeso molecular:486.93Refametinib R enantiomer
CAS:<p>Refametinib R enantiomer (RDEA119 R enantiomer) is an MEK inhibitor with an EC50 of 2.0-15 nM.Refametinib (R enantiomer) has anticancer activity and can be used</p>Fórmula:C19H20F3IN2O5SPureza:99.86%Cor e Forma:SolidPeso molecular:572.34KRAS G12C inhibitor 37
CAS:<p>KRAS G12C inhibitor 37 targets a key signaling protein, showing promise for cancer research involving KRAS G12C.</p>Fórmula:C35H39F3N8O2Cor e Forma:SolidPeso molecular:660.73(rel)-AR234960
CAS:(rel)-AR234960 is an active relative configuration of AR234960. AR234960 is a non-peptide agonist of MAS.Fórmula:C27H30FN5O5SCor e Forma:SolidPeso molecular:555.63p38 MAPK-IN-6
CAS:<p>p38 MAPK-IN-6 (compound c47) is an inhibitor of p38 MAPK, exhibiting a 14% inhibition rate at a concentration of 10 μM.</p>Fórmula:C16H14BrN3OS2Cor e Forma:SolidPeso molecular:408.336Everafenib
<p>Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.</p>Fórmula:C20H23ClFN5O2S2Cor e Forma:SolidPeso molecular:484.01Famlasertib
CAS:<p>Famlasertib is a potent inhibitor of the mitogen-activated protein kinase kinase kinase kinase (MAP4K) family, capable of penetrating the brain. It exhibits an IC50 value of 0.3 nM for HGK (MAP4K4) and 23.7 nM for MLK3.</p>Fórmula:C26H27ClN4OCor e Forma:SolidPeso molecular:446.97210-Methoxy-canthin-6-one
CAS:<p>10-Methoxy-canthin-6-one (Mtx-C) acts as a DNA damage inducer that embeds into DNA, promoting cell cycle arrest at the G2/M phase. This process triggers myeloid differentiation in acute myeloid leukemia cells (AML) and leukemia stem cells (LSC). Differentiation in AML and LSC cells is characterized by increased expression of myeloperoxidase, CD15, CD11b, and CD14, along with the activation of p38 MAPK. 10-Methoxy-canthin-6-one is utilized in the study of leukemia.</p>Fórmula:C15H10N2O2Cor e Forma:SolidPeso molecular:250.25TH-Z816
CAS:<p>TH-Z816 acts as a reversible inhibitor targeting the KRAS(G12D) mutation, exhibiting an IC50 of 14 µM. This compound is utilized in cancer research [1].</p>Fórmula:C29H38N6OCor e Forma:SolidPeso molecular:486.65Calderasib
CAS:<p>Calderasib (MK-1084) is a selective KRAS G12C inhibitor (IC50 1.2 nM) with anticancer activity, usable as monotherapy or combined with PD-1 inhibitors</p>Fórmula:C32H31ClF2N6O4Pureza:98.69%Cor e Forma:SolidPeso molecular:637.08G12Si-1
<p>G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.</p>Fórmula:C29H32ClN5O3Cor e Forma:SolidPeso molecular:534.05HPK1-IN-41
CAS:<p>HPK1-IN-41 (compound Z389) functions as an HPK1 inhibitor, exhibiting an IC50 value of 0.21 nM [1].</p>Fórmula:C28H33N5O2Cor e Forma:SolidPeso molecular:471.59(+)-Perillyl alcohol
CAS:<p>(+)-Perillyl alcohol (0.25-1 mM) inhibits cell growth in SW480 cells. At a concentration of 1 mM and a duration of 24 hours, (+)-Perillyl alcohol increases the number of cells in the G0/G1 phase and reduces the number in the S phase in SW480 cells.</p>Fórmula:C10H16OCor e Forma:SolidPeso molecular:152.23MAP855
CAS:<p>MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.</p>Fórmula:C28H23ClF2N6O3Cor e Forma:SolidPeso molecular:564.97SOS1-IN-10
<p>SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).</p>Fórmula:C22H19F5N4OCor e Forma:SolidPeso molecular:450.4KRAS G12D inhibitor 1
CAS:<p>KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].</p>Fórmula:C33H32F2N6O2Cor e Forma:SolidPeso molecular:582.64p38-α MAPK-IN-5
CAS:<p>p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.</p>Fórmula:C37H49N11O2Cor e Forma:SolidPeso molecular:679.86KRAS ligand 3
CAS:<p>KRAS ligand 3 (compound 1), a BTX-6654 target-binding ligand, exhibits synergistic tumor growth inhibition through its capacity to bind a KRAS inhibitor [1].</p>Fórmula:C24H28F3N5Cor e Forma:SolidPeso molecular:443.51pan-KRAS-IN-17
CAS:<p>pan-KRAS-IN-17 (Example 34) is an inhibitor that targets multiple forms of the KRAS protein.</p>Fórmula:C34H33F3N5O8PCor e Forma:SolidPeso molecular:727.623COTI-219
CAS:<p>COTI-219 is an oral inhibitor of KRAS with antitumor properties [1].</p>Fórmula:C17H18N6SCor e Forma:SolidPeso molecular:338.43KRAS G12D inhibitor 11
CAS:<p>KRAS G12D inhibitor 11 targets KRAS G12D in cancer research (patent WO2021108683A1, compound 52).</p>Fórmula:C29H38BN5O3Cor e Forma:SolidPeso molecular:515.45AM-001
CAS:AM-001 is a non-competitive inhibitor of Epac1, preventing the activation of its downstream effector Rap1 in cultured cells. This compound is utilized in research related to cardiac diseases.Fórmula:C24H16FN3OS2Cor e Forma:SolidPeso molecular:445.53Casein kinase 1δ-IN-31
CAS:<p>Casein kinase1δ-IN-31 (Compound 16) is an inhibitor of casein kinase (CK), specifically targeting CK1α, CK1δ, and p38α, with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, Casein kinase1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM.</p>Fórmula:C17H13FN4Cor e Forma:SolidPeso molecular:292.31SOS2 ligand 1
CAS:<p>SOS2 ligand 1 (compound 2) is a selective ligand for son of sevenless 2 (SOS2), exhibiting a KD value of 4.6 µM.</p>Fórmula:C19H21N5OCor e Forma:SolidPeso molecular:335.403ERK-IN-2
CAS:<p>ERK-IN-2, an ERK2 inhibitor, exhibits an IC50 value of 1.8 nM. At doses greater than 10 μM, it may induce off-target toxicity and/or activity [1].</p>Fórmula:C16H18ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:347.80KRASG12C IN-12
CAS:<p>KRASG12C IN-12 (compound-1) acts as an inhibitor of KRASG12C. It forms a ternary complex with intracellular CYPA and the activated mutant of KRASG12C.</p>Fórmula:C29H39N5O6S2Cor e Forma:SolidPeso molecular:617.78SML-10-70-1
CAS:<p>SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.</p>Fórmula:C25H42ClN7O13P2Cor e Forma:SolidPeso molecular:746.04Dorrigocin A
CAS:<p>Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.</p>Fórmula:C27H41NO8Cor e Forma:SolidPeso molecular:507.616KRAS inhibitor-36
CAS:<p>KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.</p>Fórmula:C14H13NO4Cor e Forma:SolidPeso molecular:259.26Brimarafenib
CAS:<p>Brimarafenib is a selective RAF dimerization inhibitor, which can inhibit BRAF and CRAF, and exhibits inhibitory effects on a variety of RAF mutations.</p>Fórmula:C24H17F3N4O4Pureza:98.32%Cor e Forma:SolidPeso molecular:482.41MK2-IN-4
CAS:<p>MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.</p>Fórmula:C25H24N4O2Cor e Forma:SolidPeso molecular:412.48SOF-436
CAS:<p>SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.</p>Fórmula:C15H13F2NO4S2Cor e Forma:SolidPeso molecular:373.395JAK3-IN-13
<p>JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.</p>Fórmula:C25H33ClN6O5Cor e Forma:SolidPeso molecular:533.02LZTR1-KRAS modulator 1
CAS:<p>LZTR1-KRAS modulator 1 is a regulator of the KRAS-LZTR1 interaction, enhancing the recruitment of the LZTR1-KRAS complex.</p>Fórmula:C11H11Cl2NOCor e Forma:SolidPeso molecular:244.12HPK1-IN-14
CAS:<p>HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.</p>Fórmula:C24H23FN6O2Cor e Forma:SolidPeso molecular:446.48pan-Raf/RTK inhibitor 1
CAS:<p>Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.</p>Fórmula:C29H28F3N7O3Cor e Forma:SolidPeso molecular:579.573MBA-m1
CAS:<p>MBA-m1 is an MLKL inhibitor that suppresses necroptosis in Mlkl−/−NIH-3T3 cells. Additionally, MBA-m1 alleviates disease conditions in mouse models of dermatitis and abdominal aortic aneurysm induced by MLKL.</p>Fórmula:C27H21ClN2O2Cor e Forma:SolidPeso molecular:440.92ZCL279
CAS:<p>ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.</p>Fórmula:C24H18N2O7S2Cor e Forma:SolidPeso molecular:510.539Anti-osteoporosis agent-11
CAS:<p>Anti-osteoporosis agent-11 (compound 3k) is an anti-osteoporosis compound targeting osteoclasts. It exhibits its most prominent effect by inhibiting osteoclast differentiation, with an IC50 value of 0.36 μM. Additionally, Anti-osteoporosis agent-11 suppresses osteoclast formation, bone resorption, and the expression of osteoclast-specific genes by blocking the RANKL-induced mitogen-activated protein kinase (MAPK) and NF-κB signaling pathways.</p>Fórmula:C23H17NO2Se2Cor e Forma:SolidPeso molecular:497.31EBI-1051
CAS:<p>EBI-1051 is a highly potent and orally efficacious inhibitor of MEK (IC50: 3.9 nM).</p>Fórmula:C18H15F2IN2O5Pureza:98%Cor e Forma:SolidPeso molecular:504.22
